We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCLIN
RNS Number : 1749M
Clinigen Group plc
12 October 2016
12 October 2016
Annual Report and Accounts and AGM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceuticals and services group, announces that its annual report and accounts for the year ended 30 June 2016 is now available on the Group's website at www.clinigengroup.com.
Copies of the Annual Report and Accounts will be posted to shareholders later today.
The Group will hold its Annual General Meeting ('AGM') on 11 November 2016 at 10.00am at Instinctif Partners' offices, 65 Gresham Street, London EC2V 7NQ. Shaun Chilton, Group Chief Executive Officer-designate, will give a presentation at the AGM. The slides will be made available on the Group's website after the meeting. No new material information will be provided.
- Ends -
Contact Details
Hot Features
Premium
Clinigen Group plc Tel: +44 (0) 1283
495010
Peter George, Group Chief
Executive Officer
Shaun Chilton, Group Chief
Executive Officer-designate
Martin Abell, Group Chief
Financial Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
Peel Hunt LLP - Joint Broker Tel: +44 (0) 20
7418 8900
James Steel / Dr Christopher
Golden
Instinctif Partners Tel: +44 (0) 20
7457 2020
Adrian Duffield / Melanie
Toyne-Sewell / Jayne Crook Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACSGBBDGLBBBGLB
(END) Dow Jones Newswires
October 12, 2016 02:00 ET (06:00 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
